OBX Obsidian Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2130606 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.9%
Debt / equity0.00x
Current ratio12.29x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $0 | — | — | $0 | — | — |
| R&D expense | $27.55M | — | — | $25.05M | — | — |
| SG&A expense | $10.32M | — | — | $4.59M | — | — |
| Operating income | -$52.91M | — | — | -$29.63M | — | — |
| Pretax income | -$50.66M | — | — | -$28.47M | — | — |
| Income tax | $0 | — | — | $0 | — | — |
| Net income | -$50.66M | -$25.86M | -$19.63M | -$28.47M | -$26.90M | -$24.99M |
| EPS (basic) | -1.23 | — | — | -14.77 | — | — |
| EPS (diluted) | -1.23 | — | — | -14.77 | — | — |
| Weighted avg. shares (diluted) | 41.03M | — | — | 1.93M | — | — |
| Balance sheet | ||||||
| Cash & equivalents | $66.51M | $0 | — | $37.36M | — | — |
| Short-term investments | $148.40M | — | — | — | — | — |
| Current assets | $224.54M | $0 | — | — | — | — |
| PP&E, net | $961,000 | — | — | — | — | — |
| Total assets | $340.74M | $0 | — | — | — | — |
| Current liabilities | $18.26M | $0 | — | — | — | — |
| Total liabilities | $20.16M | $299.71M | — | — | — | — |
| Shareholders' equity | $320.58M | -$299.71M | -$276.20M | -$247.63M | -$221.44M | -$197.30M |
| Shares outstanding | 61.77M | 1,000 | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | — | $0 | — | — | — | — |
| Investing cash flow | — | $0 | — | — | — | — |
| Financing cash flow | — | $0 | — | — | — | — |
| Stock-based compensation | $2.26M | — | — | $2.23M | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.